BIO-key Raises $2.51M via Warrant Exercise, Issues New Warrants at $4.06
BKYI sits 20% above its 52-week low of $3.1.
Summary
BIO-key raised $2.51 million by inducing an institutional investor to exercise existing warrants at a reduced price, in exchange for new warrants covering twice as many shares.
Key Events · Financing and Capital Events · BKYI
-
Warrant Exercise Agreement
BIO-key entered into an agreement with Armistice Capital to exercise 618,334 existing warrants at a reduced price of $4.06 per share, down from $10.20.
-
New Warrants Issued
In exchange, the investor received 1,236,668 new warrants with an exercise price of $4.06, subject to shareholder approval and a 4.99% beneficial ownership limitation.
-
Proceeds and Use
Gross proceeds were approximately $2.51 million, before placement agent fees of 5.0% to Maxim Group LLC. Proceeds will fund working capital and may repay a portion of the outstanding secured note.
-
Shareholder Approval Required
The company must hold a shareholder meeting within 120 days to approve the exercisability of the new warrants, with subsequent meetings every 90 days if approval is not obtained.
Analysis · BKYI · Technology
BIO-key entered into a warrant exercise agreement with Armistice Capital, reducing the exercise price of 618,334 existing warrants from $10.20 to $4.06 and issuing 1,236,668 new warrants at the same price. The company received approximately $2.51 million in gross proceeds, which will be used for working capital and possibly debt repayment. The new warrants are subject to shareholder approval and carry a 4.99% beneficial ownership limitation. This financing provides needed liquidity but adds potential future dilution if the new warrants are exercised.
At the time of this filing, BKYI was trading at $3.73 on NASDAQ in the Technology sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $3.10 to $19.70. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.